Neumora Therapeutics is trading at $0.71 (-5.28%), with no clearly reported company-specific announcement explaining the September 18, 2026 decline.
- September 17 coverage of NMRA-215 toxicology discussed previously reported preclinical data, not a fresh catalyst.
- Biotech stocks broadly rallied, while Neumora moved lower, weakening the case for a sector-driven explanation.